Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
Serum neutralizing antibodies against the human immunodeficiency virus were frequently detected in infected individuals, and low or absent serum neutralizing titers correlated with poor prognosis. Multiple diverse human immunodeficiency virus isolates were found to exhibit similar susceptibility to neutralization by a panel of human seropositive sera, suggesting that neutralizing antibodies are largely directed against conserved viral domains. Furthermore, utilizing antisera raised against a library of synthetic env peptides, four regions which are important in the neutralization process have been identified within both human immunodeficiency virus envelope glycoproteins (gp41 and gp120). Three of these are in conserved domains and should be considered for inclusion in a candidate vaccine.
D000386:AIDS-Related Complex / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies; D006801:Humans; D008297:Male; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D011379:Prognosis; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D000939:Epitopes; D006023:Glycoproteins; D015483:HIV Antibodies; D010446:Peptide Fragments; D014759:Viral Envelope Proteins